Horizon Therapeutics Public Limited (NASDAQ:HZNP) has been assigned a consensus recommendation of “Buy” from the twelve analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $125.82.
Several brokerages have recently commented on HZNP. Zacks Investment Research downgraded Horizon Therapeutics Public from a “buy” rating to a “hold” rating and set a $124.00 price objective on the stock. in a research report on Friday, October 29th. BMO Capital Markets boosted their target price on Horizon Therapeutics Public from $118.00 to $132.00 and gave the stock an “outperform” rating in a research report on Thursday, August 5th. Morgan Stanley boosted their target price on Horizon Therapeutics Public from $103.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, August 26th. Jefferies Financial Group started coverage on Horizon Therapeutics Public in a research report on Wednesday, October 13th. They issued a “buy” rating and a $132.00 target price on the stock. Finally, The Goldman Sachs Group upgraded Horizon Therapeutics Public from a “neutral” rating to a “buy” rating and set a $168.00 target price on the stock in a research report on Thursday, November 18th.
In other news, EVP Andy Pasternak sold 30,168 shares of the stock in a transaction on Thursday, November 4th. The stock was sold at an average price of $113.04, for a total transaction of $3,410,190.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Timothy P. Walbert sold 25,000 shares of the company’s stock in a transaction on Monday, November 1st. The shares were sold at an average price of $118.49, for a total value of $2,962,250.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 202,832 shares of company stock worth $22,521,442. Insiders own 3.20% of the company’s stock.
Shares of HZNP traded up $0.06 during trading hours on Friday, hitting $104.87. The stock had a trading volume of 1,772,297 shares, compared to its average volume of 1,580,562. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.83 and a quick ratio of 2.55. Horizon Therapeutics Public has a 12 month low of $66.41 and a 12 month high of $120.54. The firm has a market capitalization of $23.79 billion, a PE ratio of 45.20, a PEG ratio of 1.36 and a beta of 1.03. The stock has a fifty day moving average price of $111.43 and a 200 day moving average price of $102.92.
Horizon Therapeutics Public (NASDAQ:HZNP) last released its earnings results on Wednesday, November 3rd. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.54 by $0.21. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $979.49 million. Horizon Therapeutics Public had a return on equity of 26.85% and a net margin of 18.66%. Horizon Therapeutics Public’s quarterly revenue was up 62.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.74 earnings per share. As a group, analysts anticipate that Horizon Therapeutics Public will post 4.29 EPS for the current fiscal year.
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.
Featured Article: Producer Price Index (PPI)
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.